Drug profile

The FDA adverse-event record for Cyclosporine Ophthalmic

23 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Cyclosporine Ophthalmic. Species, reactions, and outcomes follow.

#1642 of 2,679
by report volume (all drugs)
23
adverse-event reports
26.1%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Cyclosporine Ophthalmic ranks #1638 of 2679 by total reports (23). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1638
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Cyclosporine Ophthalmic has 23 reports now versus 22 in that prior snapshot: 1 more (4.5%).

Report change
+1
Death-coded reports
+0
Death-coded share
−1.2 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Cyclosporine Ophthalmic changes

Signature read: Cyclosporine Ophthalmic's 26.1% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
23
Total Reports
6
Deaths Reported
26.1%
Death-coded share of reports

Active Ingredients

Cyclosporine Ophthalmic

Administration Routes

OphthalmicUnknownOther

Species Affected

Dog 23

Most Affected Breeds

Shih Tzu 4
Crossbred Canine/dog 3
Terrier - Yorkshire 2
Dog (unknown) 2
Terrier - Boston 2
Spaniel - King Charles Cavalier 2
Pug 2
Schnauzer - Miniature 1
Bichon Frise 1
Bulldog - English 1

Most Reported Reactions

Seizure NOS 6
Elevated blood urea nitrogen (BUN) 4
Tremor 3
Death by euthanasia 3
Vomiting 3
Elevated alanine aminotransferase (ALT) 3
Lethargy (see also Central nervous system depression in Neurological) 3
Elevated globulins 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Uncoded sign 2
Dehydration 2
Fever 2

Outcome Breakdown

Outcome Unknown
7 (30.4%)
Ongoing
6 (26.1%)
Euthanized
3 (13.0%)
Recovered/Normal
3 (13.0%)
Died
3 (13.0%)
Recovered with Sequela
1 (4.3%)

Cyclosporine Ophthalmic: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Cyclosporine Ophthalmic (#1642 of 2,679 by report volume); death-coded 26.1%. PlainBreed drug row · death-coded share stamp 26.1% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →